James said :-4 Nov 2020 12:12
James Normand, Executive Director of Vela, commented:
"Vela is pleased to have been invited to participate in such a prestigious and genuinely ground-breaking project as this and is delighted to invest alongside internationally respected stakeholders such as Professor Sir Christopher Evans, UKRI and Mubadala. The Board of Vela looks forward to providing shareholders with news on the outcome of these trials as this highly regarded team pursues its quest for a drug to provide a therapeutic treatment for the effects of COVID-19 on diabetic patients."